EyePoint Pharmaceuticals Faces Major Investor Investigation Following Phase‑3 Trial Results
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) encountered a significant market downturn after the company announced that its investigational drug DURAVYU failed to meet the prespecified primary endpoint in the Phase 3 LUGANO trial for wet age‑related macular degeneration. The trial results were disclosed on August 17, 2026, and the company’s shares fell roughly 70% at the market opening that day.
Key Facts About EyePoint Pharmaceuticals
- Industry: Pharmaceuticals (biopharmaceuticals)
- Sector: Health Care
- Exchange: Nasdaq
- Market Capitalization: $430.2 million (USD)
- Close Price (2026‑08‑26): $4.63
- 52‑Week High: $19.11 (2025‑12‑07)
- 52‑Week Low: $3.95 (2026‑08‑16)
- Price/Earnings Ratio: –1.33 (negative earnings)
The company specializes in developing drug‑delivery devices for eye diseases and other chronic conditions. It went public on January 27, 2005 and serves a global customer base.
LUGANO Trial Results and Market Impact
- DURAVYU did not achieve the primary endpoint of change in best‑corrected visual acuity versus on‑label aflibercept in the full dataset.
- Secondary outcomes were favorable, reporting a 42 % reduction in treatment burden and an ad‑hoc analysis excluding a 4 % asymmetric patient cohort.
- Despite the positive secondary data, the primary endpoint failure led to a market opening decline of about $10.69 per share (≈ 72.47 %) and a midday drop exceeding 68 %.
- By the close of trading, the loss had stabilized to a reduction of roughly $9.88 per share (≈ 67 %).
Investor Investigation Notices
Three separate legal firms have issued investigations for investors who incurred losses:
| Date | Source | Firm | Action Encouraged |
|---|---|---|---|
| 2026‑08‑26 | ceo.ca | Kessler Topaz Meltzer & Check LLP | Encourage EYPT investors to contact the firm |
| 2026‑08‑26 | ceo.ca | SBS Law | Invite investors to join the fraud investigation |
| 2026‑08‑26 | prnewswire.com | Levi & Korsinsky LLP | Offer a no‑cost evaluation for potential securities‑fraud claims |
Levi & Korsinsky LLP specifically states that investors who purchased EYPT securities and suffered losses may submit brokerage records for an evaluation of possible recovery. The firm highlights its 20‑year track record of securing hundreds of millions of dollars for aggrieved shareholders and its ranking in the ISS Securities Class Action Services Top 50 Report.
Investor Eligibility and Process
- Investors are eligible based on purchase date, share quantity, and documented losses, not on current ownership status.
- Required documentation includes brokerage statements or trade confirmations showing purchase dates, share quantities, and prices paid.
- Investors may submit their information online or contact the firm by email or telephone for a no‑cost, no‑obligation review.
Current Market Status
As of August 28, 2026, the company’s shares remain significantly depressed relative to their 52‑week low. The market continues to digest the implications of the trial data and the potential regulatory or legal actions stemming from the investor investigations.
All information is derived from the provided financial and news data concerning EyePoint Pharmaceuticals, Inc.
